X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $34.50.

Several analysts recently commented on the company. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Wall Street Zen downgraded shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th.

X4 Pharmaceuticals Trading Down 2.7%

Shares of NASDAQ XFOR opened at $3.56 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $17.10. The firm has a 50 day moving average price of $3.83 and a two-hundred day moving average price of $3.40. The stock has a market cap of $311.29 million, a P/E ratio of -0.35 and a beta of 0.46.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.10. The company had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. As a group, equities analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Indivisible Partners bought a new stake in X4 Pharmaceuticals in the fourth quarter worth approximately $40,000. Palumbo Wealth Management LLC grew its position in shares of X4 Pharmaceuticals by 18.9% during the 4th quarter. Palumbo Wealth Management LLC now owns 113,357 shares of the company’s stock worth $453,000 after buying an additional 18,030 shares during the period. Acorn Capital Advisors LLC increased its stake in shares of X4 Pharmaceuticals by 77.8% in the 3rd quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company’s stock valued at $935,000 after acquiring an additional 119,619 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter valued at $7,621,000. Finally, Kingdon Capital Management L.L.C. lifted its position in shares of X4 Pharmaceuticals by 300.0% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after acquiring an additional 700,000 shares during the period. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.